Title: New Advances in PDAC Treatment

Speaker

Manuel Hidalgo, MD, PhD
Clinical Director of the Cancer Center and Chief of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

Chairman

Yuko Kitagawa, MD, PhD
Professor, Department of Surgery, Graduate School of Medicine, Keio University, Japan

Dr. Manuel Hidalgo

Profile

Dr. Hidalgo, an internationally respected oncologist whose groundbreaking work in experimental cancer therapy and tumor model development has led to key advances in the treatment of pancreatic cancer, has been named Director of the Leon V. & Marilyn L. Rosenberg Clinical Cancer Center and Chief of the Division of Hematology-Oncology at Beth Israel Deaconess Medical Center (BIDMC). A native of Spain, He comes to BIDMC from the Centro Nacional de Investigaciones Oncologicas (Spanish National Cancer Center) where he serves as Director of the Clinical Research Program and Vice Director of Translational Research. He holds faculty positions at University CEU San Pablo and Johns Hopkins University.

He received his medical degree from the University of Navarra and his PhD from the University Autonoma of Madrid. He completed a fellowship in anticancer drug development at the University of Texas Health Science Center in San Antonio. In 2001, He joined Johns Hopkins as an associate professor and in 2003, became co-director of its newly created Gastrointestinal Cancer Program. He joined the Spanish National

Cancer Center in 2009. He is a founder of the Pancreatic Cancer Research Team (PCRT), a private nonprofit cooperative group dedicated to rapid drug development in pancreatic cancer.

Recent Publications

Ambrogio C, Gómez-López G, Falcone M, Vidal A, Nadal E, Crosetto N, Blasco RB, Fernández-Marcos PJ, Sánchez-Céspedes M, Ren X, Wang Z, Ding K, **Hidalgo M**, Serrano M, Villanueva A, Santamaría D, Barbacid M. Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. *Nat Med*. 2016 Mar; 22(3):270-7.

Kim H, Samuel S, Lopez-Casas P, Grizzle W, **Hidalgo M**, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. *Mol Cancer Ther*. 2016 Apr; 15(4):680-8.

Kim H, Samuel S, Lopez-Casas P, Grizzle W, **Hidalgo M**, Kovar J, Oelschlager D, Zinn K, Warram J, Buchsbaum D.SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. *Mol Cancer Ther*. 2016 Apr; 15(4):680-8.

Xie T, Musteanu M, Lopez-Casas PP, Shields DJ, Olson P, Rejto PA, **Hidalgo M.** Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. *PLoS One*. 2015 Nov 10; 10(11):e0142631.

Gomez-Rubio P, Zock JP, Rava M, Marquez M, Sharp L, **Hidalgo M**, Carrato A, Ilzarbe L, Michalski C, Molero X, Farré A, Perea J, Greenhalf W, O'Rorke M, Tardón A, Gress T, Barberà V, Crnogorac-Jurcevic T, Domínguez-Muñoz E, Muñoz-Bellvís L, Alvarez-Urturi C, Balcells J, Barneo L, Costello E, Guillén-Ponce C, Kleeff J, Kong B, Lawlor R, Löhr M, Mora J, Murray L, O'Driscoll D, Peláez P, Poves I, Scarpa A, Real FX, Malats N; PanGenEU Study Investigators. Reduced risk of pancreatic cancer associated with asthma and nasal allergies. *Gut*. 2015 Dec 1. pii: gutjnl-2015-310442.

Hidalgo M, Plaza C, Musteanu M, Illei P, Brachmann CB, Heise C, Pierce D, Lopez-Casas PP, Menendez C, Tabernero J, Romano A, Wei X, Lopez-Rios F, Von Hoff DD. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. *Clin Cancer Res*. 2015 Nov 1; 21(21):4811-8.

.